Table 2 Adverse events for the ovarian cancer patients treated with IDS plus HIPEC (n = 121) and IDS alone (n = 76)
Adverse events n (%) | Grade I or II | Grade III or IV | ||
|---|---|---|---|---|
IDS + HIPEC | IDS alone | IDS + HIPEC | IDS alone | |
Haematology | ||||
 Leucocytopenia | 21 (17.4) | 2 (2.6) | 0 | 0 |
 Thrombocytopenia | 9 (7.4) | 0 | 0 | 0 |
 Anemia | 30 (24.8) | 18 (23.7) | 1 (0.8) | 2 (2.6) |
Electrolyte disturbance* | 38 (31.4) | 20 (26.3) | 4 (3.3) | 2 (2.6) |
Thromboembolism | 10 (8.3) | 5 (6.6) | 3 (2.5) | 2 (2.6) |
Nausea | 27 (22.3) | 15 (19.7) | 0 | 0 |
Emesis | 16 (13.2) | 9 (11.8) | 0 | 0 |
Nephrotoxicity | 5 (4.1) | 0 | 0 | 0 |
Abdominal pain | 26 (21.5) | 13 (17.1) | 2 (1.7) | 0 |
Ileus | 6 (5.0) | 2 (2.6) | 10 (8.3) | 5 (6.6) |
Anastomotic hemorrhage | 4 (3.3) | 3 (3.9) | 2 (1.7) | 0 |
Infection | 15 (12.4) | 11 (14.5) | 3 (2.5) | 3 (3.9) |